Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK573719/GW642444 in COPD
NCT01313637Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2011
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of umeclidinium, vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Mar 2011; status: completed.
02
Drugs
umeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01313637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313637.